Quantcast
Last updated on April 18, 2014 at 8:37 EDT

Latest Quinazolines Stories

2012-04-09 02:24:07

WALTHAM, Mass., April 9, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin®). The study...

2012-04-02 02:27:42

CHICAGO and AUSTIN, Texas, April 2, 2012 /PRNewswire/ -- Genprex, Inc. -- New data demonstrating the anti-cancer activities of Oncoprex® were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, IL. The study, "Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC" (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored by a team of investigators from The University of Texas MD Anderson...

2012-03-16 08:50:41

WASHINGTON, March 16, 2012 /PRNewswire/ -- Oral cancer drugs that target key enzymes in tumor cells have made significant contributions to oncology care, freeing many patients from spending long hours at infusion centers to receive their chemotherapy treatments. But new research shows that many patients using these oral medications are also on other drugs that may prevent patients from getting the full benefit from their cancer treatment, or increase the risk of side effects. (Logo:...

2012-03-06 10:16:58

Mayo Clinic researchers this week will announce the use of the blood pressure drug prazosin as an effective treatment to curb post- traumatic stress disorder (PTSD)-related nightmares. In a presentation during the 20th European Congress of Psychiatry in Prague, Mayo Clinic psychiatrists will present a systematic literature review of prazosin in the treatment of nightmares. Researchers investigated 12 prazosin studies, four of which were randomized controlled trials. "The studies showed...

2012-01-26 11:57:14

Head and neck cancers respond well to the anti-cancer drug erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM. Erlotinib is an oral anti-cancer drug that can slow a tumor's growth and spread by inhibiting specific growth receptors on the surface of the cancer cells. Early detection of a patient's response to EGFR...

2012-01-19 15:06:30

    The most common form of lung cancer inevitably develops resistance to the targeted drug gefitinib.     This study shows how this resistance develops.     The findings suggest a new strategy for treating non-small cell lung cancer. New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain...

2012-01-05 07:30:00

WALTHAM, Mass. and TUCSON, Ariz., Jan. 5, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. and Ventana Medical Systems, Inc. announced that the companies have entered into an agreement to develop a companion diagnostic assay to select patients with non-small cell lung cancer (NSCLC) for treatment with erlotinib and Syndax's proprietary lead molecule entinostat. "Syndax is pleased to partner with Ventana, a world leader and innovator of tissue-based diagnostic solutions for patients...

2011-12-09 08:00:00

LOS ANGELES, Dec. 9, 2011 /PRNewswire/ -- Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas. These presentations are further detailed below: Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients...

2011-11-18 15:19:00

CAMBRIDGE, Mass., Nov. 18, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with erlotinib (Tarceva®), a small molecule directed at the epidermal growth factor receptor (EGFR), in three groups of patients with metastatic non-small cell lung cancer (NSCLC). (Logo: <font size="2"...

2011-11-09 10:12:25

Method can be implemented into routine clinical practice, bringing effective personalized medicine a step closer Researchers in the United States have shown, for the first time, that it is possible to screen cancer patients for a broad range of cancer-causing genetic mutations as part of normal clinical practice. By identifying patients' individual genotypes within a relatively short time frame, doctors are able to target tumors with the most appropriate therapy. The study, which is...